Compare Incyte Corporation (INCY) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Snowflake Inc — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Snowflake Inc trades at $368.89 (market cap $121.15B). The key difference: Snowflake Inc is far larger — about 5.3× Incyte Corporation's market cap, and Snowflake Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Snowflake Inc for 54 Days on average.
| INCY | SNOW | |
|---|---|---|
Market Cap | $22.85B | $121.15B |
Volume | 1,927,029 | 3,986,549 |
Sector | Health | Technology |
52-Week High | $129.93 | $368.89 |
52-Week Low | $83.80 | $121.11 |
Typical Hold Time | 33 Days | 54 Days |
Enterprise Value | $18.35B | $121.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Snowflake (SNOW) trades at $343.40, up 3.17% with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $3.63 billion in 2025 but remains unprofitable with a net income margin of -20.07%. Recent positive developments include strategic partnerships with UiPath and a $3.75 billion convertible note offering to fund growth initiatives.
Snowflake presents a growth investment opportunity with strong analyst support (81% buy ratings) and a $418 price target, but faces execution risks from persistent losses and high valuation multiples. The stock's upside depends on continued revenue expansion and path to profitability amid competitive cloud data market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
